Flufirvitide 3

Drug Profile

Flufirvitide 3

Alternative Names: FF-3; Flu-3

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tulane University School of Medicine
  • Developer Autoimmune Technologies
  • Class Antivirals; Peptides
  • Mechanism of Action HN protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-virus-infections(In volunteers) in USA (Intranasal, Spray)
  • 01 Jun 2016 Autoimmune Technologies completes a phase II trial in Healthy volunteers in United Kingdom (NCT02423577)
  • 01 Sep 2015 Phase-II clinical trials in Influenza virus infections (In volunteers) in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top